PD-1 Market Saturation

PD-1 market saturation is 小P老师’s 2025 biopharma baseline in vol.117.生物医药的2025：抄底中国、研发焦虑和新王继位. The source argues that PD-1 moved from breakthrough platform to crowded market, with especially intense domestic price competition in China.

The concept matters because it changes how the episode reads later innovation. PD-1/VEGF bispecifics are interesting not because another PD-1 label is enough, but because a new mechanism or combination could create meaningful differentiation inside a saturated field.

130. 谁才是生物医药行业发展的核心驱动力？兼谈创新药产业链的角色分工 adds a clinical-threshold version: once PD-1 and other major oncology advances improve survival baselines, later projects need stronger incremental benefit to look worthwhile to top clinicians, regulators, payers, and investors.

Key Claims

• PD-1 is treated as a mature and crowded immuno-oncology category.
• Domestic Chinese PD-1 competition makes price and differentiation problems more severe.
• K药 shows that clinical-development strategy can dominate even within the same broad mechanism class.
• New PD-1-linked assets need clinical differentiation rather than only class participation.
• Mature immuno-oncology categories raise the evidence bar for follow-on combinations.

Connections

• Merck / 默沙东, Keytruda / K药, and Bristol Myers Squibb / BMS - global PD-1 comparison in the source.
• PD-1/VEGF Bispecific and Akeso / 康方生物 - new differentiation example.
• Cancer Immune Recognition Problem - oncology logic that immunotherapy tries to exploit.
• Finite-Game Biotech Competition - mature-platform competition frame.
• Clinical Development Capability and Unmet Medical Need Demand Pull - trial and patient-need threshold context.